MNKD
USDMannKind Corporation Common Stock
वास्तविक समय मूल्य
मूल्य चार्ट
मुख्य मीट्रिक्स
बाजार मीट्रिक्स
खुलना
$5.420
उच्च
$5.600
कम
$5.410
मात्रा
4.20M
कंपनी के मौलिक सिद्धांत
बाजार पूंजीकरण
1.7B
उद्योग
जैव प्रौद्योगिकी
देश
United States
ट्रेडिंग आँकड़े
औसत मात्रा
4.75M
एक्सचेंज
NGM
मुद्रा
USD
52-सप्ताह रेंज
AI विश्लेषण रिपोर्ट
अंतिम अपडेट: 29 अक्टू॰ 2025MNKD: Bullish Momentum or Market Overreaction?
News Sentiment Analysis
Recent developments highlight major progress for MannKind:
- FDA review acceptance of their pediatric inhaled insulin application (Afrezza) opens a new market for diabetes therapy
- Analyst reaffirms $11 price target -- 105% above current levels -- signaling long-term optimism
- CMO appointment indicates leadership strengthening for clinical pipeline execution
However, AI sentiment scoring remains neutral despite positive news, suggesting market skepticism or delayed reaction.
Price Action Review
Historical data shows extreme volatility in recent months:
- August 27 crash: From $4.52 → $5.74 in one day (27% drop)
- October 10 low: $4.88 (32% below August high)
- Recovery phase: 11% bounce since October 13 ($4.92 → $5.42)
Technical indicators conflict:
- Bullish MACD crossover and OBV surge (2.6x average volume)
- Bearish DMI trend (ADX 15.9) and proximity to key support ($5.42)
Volume patterns suggest accumulation at support levels during recent declines.
Predictive Outlook
AI models project a steady short-term uptrend:
- Day 1: +0.25% → $5.43
- Day 2: +3.17% → $5.59
- Day 3: +4.16
संबंधित समाचार
MannKind Corporation to Hold 2025 Third Quarter Financial Results Conference Call on November 5, 2025
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD), announced today that its third quarter 2025 financial results will be released before the market opens
MannKind Announces U.S. FDA Accepts for Review its Supplemental Biologics License Application (sBLA) for Inhaled Insulin (Afrezza) in Children and Adolescents Aged 4-17 Years Living with Diabetes
If approved, it would be the first needle-free insulin option for pediatric patients in 100+ years of insulin therapysBLA submission based on data from the Phase 3 INHALE-1 study PDUFA target action date of May 29, 2026
HC Wainwright & Co. Reiterates Buy on MannKind, Maintains $11 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates MannKind with a Buy and maintains $11 price target.
AI भविष्यवाणीBeta
AI सिफारिश
पर अपडेट किया गया: 5 नव॰ 2025, 09:21 am
69.1% आत्मविश्वास
जोखिम और ट्रेडिंग
प्रवेश बिंदु
$5.51
लाभ लें
$5.88
स्टॉप लॉस
$4.94
मुख्य कारक
संबंधित स्टॉक
अपडेट रहें
मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।